Back

Continuing sodium-glucose cotransporter-2 inhibitors after transcatheter aortic valve implantation improves survival and renal outcomes

28 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Improving management in transcatheter aortic valve intervention Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Yu-Chuan Chuang

Taichung (Taiwan)

6 More presentations in this session

Presentation thumbnail
Impact of right atrial remodeling on mortality after transcatheter aortic valve implantation
Doctor K. Guzman Valencia (Madrid, ES)
Abstract Slides
Presentation thumbnail
Impact of aortic annulus size on clinical and hemodynamic outcomes of transcatheter aortic valve implantation with the navitor valve
Doctor J. Capparelli (Rome, IT)
Abstract Slides
Presentation thumbnail
Clinical yield of discharge transthoracic echocardiography in transcatheter aortic valve implantation patients from a contemporary cohort
Mr O. Ward (DK)
Abstract Slides
Presentation thumbnail
Temporal trends of TAVI waiting times in a tertiary centre: from initial implementation to contemporary practice
Doctor G. Zaburaite (Vilnius, LT)
Abstract Slides
Presentation thumbnail
Carbohydrate antigen 125 as a predictor of mortality and heart failure outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis
Doctor L. Cintia (Bs As, AR)
Abstract Slides

Access the full session

Session thumbnail
Improving management in transcatheter aortic valve intervention

The Event

Event poster

ESC Congress 2026

28 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in cancer patients: a systematic review and meta-analysis of heart failure hospitalisation and mortality.
26 April 2024
thumbnail
Congress Session
Transcatheter aortic valve implantation: outcomes, complications, and adjunctive therapy
29 August 2025
thumbnail
Congress Presentation
Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes
28 August 2020
thumbnail
Congress Presentation
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources